Human Immunology News 7.01 January 15, 2019 | |
| |
TOP STORYResearchers found that patients with T cells enriched for naive and stem central memory cells expanded well in vitro, but the majority of tumor types showed chemotherapy related depletion of early lineage cells with a corresponding decline in successful ex vivo stimulation response. [Cancer Discov] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Mutated Nucleophosmin 1 as Immunotherapy Target in Acute Myeloid Leukemia By searching the HLA class I ligandome of primary acute myeloid leukemias (AMLs), scientists identified multiple mutated nucleophosmin 1-derived peptides. For one of these peptides, HLA-A*02:01-binding CLAVEEVSL, they searched for specific T cells in healthy individuals using peptide-HLA tetramers. Tetramer-positive CD8+ T cells were isolated and analyzed for reactivity against primary AMLs. [J Clin Invest] Full Article Researchers found that a pancreatic tumor has minimal to moderate infiltration of CD3, CD4, and CD8 T cells; however, the immune infiltrates were predominantly present in the stromal area of the tumor and were excluded from tumoral area compared with melanoma, where the immune infiltrates were primarily present in the tumoral area. [Proc Natl Acad Sci USA] Abstract | Press Release The authors analyzed data from 2633 consecutive patients with Graves disease (GD), Hashimoto thyroiditis, euthyroid Hashimoto thyroiditis (EHT) and non-autoimmune thyroid disease for the presence of differentiated thyroid cancer (DTC). They investigated the microenvironment, and cellular mechanism of protection from DTC in GD/EHT by ex vivo aspirating infiltrates from thyroid samples. [J Immunother Cancer] Full Article The influence of deltex1 (DTX1) on T cell function was evaluated using human primary cells. DTX1 expression in peripheral blood mononuclear cells from healthy controls and SLE patients was measured by quantitative real-time PCR and the SLEDAI was used to assess disease activity. [Rheumatology (Oxford)] Abstract Investigators compared the TCR‐Vα/Vβ gene usage of major histocompatibility complex‐restricted antigen (MART‐1) specific T‐cells generated in vitro to that from ex vivo naïve T cells and tumor‐infiltrating lymphocytes using high‐throughput DNA sequencing. [Immunol Cell Biol] Abstract MUC16 Suppresses Human and Murine Innate Immune Responses Researchers provide evidence of the regulatory role of MUC16 on human and murine NK cells and macrophages. Target cell cytolysis and doublet formation assays were performed to assess effects of MUC16 on human NK cells. [Gynecol Oncol] Abstract The authors evaluated PCED1B-AS1 expression in the CD14+ monocytes from patients with active tuberculosis and from healthy individuals. They found that PCED1B-AS1 expression was down-regulated in patients with active tuberculosis, accompanied by significant attenuated monocyte apoptosis and enhanced autophagy. [Biochem Biophys Res Commun] Abstract Scientists assessed natural killer (NK) cell activity and various metabolic parameters in people with type 2 diabetes, prediabetes, and normal glucose tolerance. [J Diabetes Investig] Abstract | Full Article Benign T Cells Drive Clinical Skin Inflammation in Cutaneous T Cell Lymphoma In low-burden patients, psoralen plus UVA reduced or eradicated malignant T cells and induced clonal expansion of CD8+ T cells associated with malignant T cell depletion. [JCI Insight] Full Article Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSThe Expression of FOXP3 and Its Role in Human Cancers FOXP3 is a transcription factor, which belongs to the family of FOX protein. FOXP3 was initially discovered in regulatory T cells and supposed to play a significant role in the process of regulatory T cell differentiation. Increasing evidence has shown that FOXP3 is also expressed in tumor cells. [Biochim Biophys Acta Rev Cancer] Full Article Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
INDUSTRY NEWSThe University of Texas MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., announced a strategic collaboration to bring Dragonfly’s TriNKET™ immunotherapy drug candidates to patients in clinical trials beginning in 2019. [The University of Texas MD Anderson Cancer Center] Press Release NantKwest Inc. announced the launch of a novel triple combination, Phase II clinical trial in Merkel cell carcinoma. [NantKwest] Press Release | |
| |
POLICY NEWSOpen-Access Row Prompts Editorial Board of Elsevier Journal to Resign The editorial board of an influential scientometrics journal — the Journal of Informetrics — has resigned in protest over the open-access policies of its publisher, Elsevier, and launched a competing publication. [Nature News] Editorial If the Shutdown Drags on at FDA, It Will Put Anticipated New Treatments in Jeopardy The government shutdown could soon jeopardize highly anticipated new drugs from Janssen, Sanofi and Novartis for depression, diabetes and multiple sclerosis, as well as a host of other potential new therapies, according to a STAT analysis of upcoming regulatory decision dates. [STAT News] Editorial
| |
EVENTSNEW The Tumor Cell: Plasticity, Progression and Therapy Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Immunology/Immunometabolism (Technische Universitat Braunschweig) NEW PhD Student – Immunology/Cell Biology (Universitatsklinikum Munster) NEW Postdoctoral Position – Cytokine-Producing B Cells (Inserm) Research Technologist – Immunology (STEMCELL Technologies Inc.) Postdoctoral Research Associate – Immunity and Inflammation (University of Illinois – Chicago) Postdoctoral Fellow – Immunology (Yonsei Cancer Center) Postdoctoral Position – Immunology (University of California, San Francisco) Junior Principal Investigator – Immunology (Foundation FIRC Institute of Molecular Oncology) Supervisor – Transfusion Medicine – Immune, Progenitor, & Cell Therapy (Mayo Clinic) Postdoctoral Position – Natural Killer Cells (The Scripps Research Institute) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|